Pure Biologics (WAR:PUR) ROCE % : -144.98% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Pure Biologics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pure Biologics's annualized ROCE % for the quarter that ended in Mar. 2024 was -144.98%.

Pure Biologics ROCE % Historical Data

The historical data trend for Pure Biologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pure Biologics ROCE % Chart

Pure Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-68.14

-235.17

-54.19

-81.77

-178.46

Pure Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-64.14	-62.72	-45.02	-123.33	-144.98

Pure Biologics ROCE % Calculation

Pure Biologics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-31.861	/	( ( (33.009 - 12.834)	+	(22.738 - 7.206) )	/ 2 )
	=	-31.861	/	( (20.175	+	15.532)	/ 2 )
	=	-31.861	/	17.8535
	=	-178.46 %

Pure Biologics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-18.56	/	( ( (22.738 - 7.206)	+	(19.651 - 9.579) )	/ 2 )
	=	-18.56	/	( ( 15.532	+	10.072 )	/ 2 )
	=	-18.56	/	12.802
	=	-144.98 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Pure Biologics (WAR:PUR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pure Biologics ROCE % Related Terms

Thank you for viewing the detailed overview of Pure Biologics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pure Biologics (WAR:PUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PQB:Germany

Address

ul. Dunska 11, Wroclaw, POL, 54-427

Website

http://www.purebiologics.pl

Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Pure Biologics (WAR:PUR) Headlines

No Headlines